

Table 4.27

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	73,901	99.8%	58,202	99.8%	7,667	99.7%	6,873	100.0%	231	100.0%	6,603	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>f</sup>	62,662	84.6%	48,798	83.7%	6,728	87.5%	6,225	90.5%	197	85.3%	5,641	85.3%
Cribiform carcinoma <i>in situ</i> (8201/2)	6,254	8.4%	4,764	8.2%	700	9.1%	676	9.8%	21	9.1%	591	8.9%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,819	6.5%	3,891	6.7%	426	5.5%	440	6.4%	-	-	385	5.8%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,004	31.1%	18,193	31.2%	2,508	32.6%	1,959	28.5%	65	28.1%	2,009	30.4%
Comedocarcinoma <i>in situ</i> (8501/2)	5,867	7.9%	4,613	7.9%	596	7.8%	568	8.3%	33	14.3%	525	7.9%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,183	1.6%	810	1.4%	205	2.7%	142	2.1%	-	-	109	1.6%
Noninfiltrating intracystic carcinoma(8504/2)	293	0.4%	190	0.3%	44	0.6%	54	0.8%	-	-	28	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,448	2.0%	1,146	2.0%	174	2.3%	106	1.5%	-	-	129	2.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	19,612	26.5%	15,052	25.8%	2,063	26.8%	2,251	32.7%	55	23.8%	1,848	27.9%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,436	11.4%	7,161	12.3%	670	8.7%	397	5.8%	26	11.3%	725	11.0%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,410	11.4%	7,139	12.2%	666	8.7%	397	5.8%	26	11.3%	725	11.0%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	25	0.0%	22	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,326	3.1%	1,883	3.2%	221	2.9%	187	2.7%	-	-	195	2.9%
Other adenocarcinomas <sup>g</sup>	470	0.6%	354	0.6%	48	0.6%	63	0.9%	-	-	42	0.6%
Other <i>in situ</i> histologies <sup>h</sup>	154	0.2%	126	0.2%	23	0.3%	-	-	-	-	-	-
Total	74,055	100.0%	58,328	100.0%	7,690	100.0%	6,875	100.0%	231	100.0%	6,612	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>f</sup> CIS = Carcinoma *in situ*.

<sup>g</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.